Treatment of CIK for Patients With Refractory Non-Hodgkin Lymphoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Cytokine-induced killer cells (CIK).
- Who it may be relevant to
- Registry conditions: Lymphoma, Non-Hodgkin. Basic parameters: 18 years — 80 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Randomized Controlled Clinical Trial of Cytokine-induced Killer (CIK) Cells Treatment in Patients With Refractory Non-Hodgkin Lymphoma
Overview
The purpose of this study is to study the safety and efficacy of chemotherapy usage followed by CIK transfusion in refractory and/or chemoresistant lymphomas.
Detailed description
Autologous cytokine-induced killer (CIK) cells transfusion(\>2\*10\^9 cells count) within 2 weeks after regular chemotherapy every 3 months.
Interventions
- Biological Cytokine-induced killer cells (CIK)
Cytokine-induced killer (CIK) cells are able to eradicate lymphomas and other malignancies. CIK cells are generated by incubation of peripheral blood lymphocytes with an anti-cluster of differentiation 3 (anti-CD3) monoclonal antibody, interleukin-2 (IL-2), interleukin-1 (IL-1) and interferon-gamma.
Primary outcome measures
- Progression-Free-Survival (PFS) [Time frame: 1 month]
Secondary outcome measures (1)
- Overall Survival (OS) [Time frame: 1 month]
Eligibility criteria
Inclusion criteria
- diagnosed as non-Hodgkin lymphoma with negative effect of regular chemotherapy, and need further therapy
Exclusion criteria
- patients refuse the therapy or have no tolerance for the therapy
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT02497898 · RNHL001